Loading...
•
Mar 31, 2020
Arrowhead Pharmaceuticals Q2 2020 Earnings Report
Reported financial results for the fiscal second quarter ended March 31, 2020.
Key Takeaways
Arrowhead Pharmaceuticals reported a revenue of $23,528,853 and a net loss of $19,835,570 for the fiscal second quarter ended March 31, 2020.
Dosed the first patients in AROHSD1001, a Phase 1/2 clinical study of ARO-HSD.
Completed enrollment of the first sequential cohort in the AROAAT2002 study, a pilot open-label, multi-dose, Phase 2 study to assess changes in a novel histological activity scale in response to ARO-AAT over time in patients with alpha-1 antitrypsin deficiency associated liver disease.
Completed planned enrollment in AROANG1001, a Phase 1 clinical study of ARO-ANG3.
Completed discovery and optimization work and advanced ARO-Lung2 into IND-enabling studies with a planned CTA filing in in the first half of 2021.
Forward Guidance
No forward guidance was provided in the press release.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...